News & Events
-
July 21, 2015
Critical Path Institute Establishes The Global Pediatric Clinical Trials Network Pre-Launch Consortium
July 22, 2015 Critical Path Institute Establishes The Global Pediatric Clinical Trials Network Pre-Launch Consortium The Pre-Launch Consortium aims to establish the first global, multi-specialty clinical trials network dedicated to the timely and efficient development of safe and effective therapies for children. TUCSON, Ariz., July 22, 2015 — The Critical Path Institute (C-Path),...... -
June 25, 2015
Critical Path Institute Announces Appointments of Peter Hutt, Alan Levin, and Paula Olsiewski To Its Board of Directors
June 25, 2015 Critical Path Institute Announces Appointments of Peter Hutt, Alan Levin, and Paula Olsiewski To Its Board of Directors TUCSON, Ariz., June 25, 2015 — The Critical Path Institute (C-Path) is pleased to welcome three new members to its Board of Directors, each of whom has been elected to a three-year term. Joining the board...... -
June 1, 2015
Critical Path Institute Secures Regulatory Support For Autosomal Dominant Polycystic Kidney Disease (ADPKD) Biomarker
TUCSON, Ariz., June 1, 2015 — The Critical Path Institute (C-Path) announced today that the U.S. Food and Drug Administration (FDA) has issued a Letter of Support to C-Path’s Polycystic Kidney Disease Outcomes Consortium (PKDOC) for the use of total kidney volume (TKV) as a prognostic biomarker to select patients for clinical trials of new therapies for Autosomal Dominant Polycystic Kidney Disease (ADPKD).
ADPKD is a debilitating genetic disease affecting more than 600,000 Americans and 12 million people worldwide. It is characterized by progressive enlargement of the kidneys due to the formation and growth of cysts. TKV is a measurement of the impact of ADPKD on the size of the kidneys and is believed to be predictive of a future decline in kidney function -
May 19, 2015
Critical Path Institute Launches New Neonatal Consortium
May 19, 2015 Critical Path Institute Launches New Neonatal Consortium The International Neonatal Consortium (INC) aims to accelerate the development of safe, effective therapies for newborns. TUCSON, Ariz., May 19, 2015 — Today, the Critical Path Institute (C-Path), a pioneering non-profit organization dedicated to accelerating the pace and reducing the costs of medical product development...... -
May 4, 2015
C-Path Selected as Host For New TB Clinical Trial Data-Sharing Platform
May 4, 2015 Host For New TB Clinical Trial Data-Sharing Platform Selected TUCSON, Ariz., May 4, 2015 — The non-profit Critical Path Institute has been selected to host a new tuberculosis (TB) clinical trial data sharing platform. The initiative will start by creating a common database from three Phase III clinical trials earlier supported by......